Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
10 pending office actions • 7 art units • 8 examiners • 0 of 10 (0%) have an AI response strategy ready • 9 patents granted in the last 365 days
Compass Pathfinder Limited manages a company patent portfolio in the Biotechnology & Pharmaceuticals technology area. The portfolio currently has 9 pending office actions. These actions are distributed among 8 distinct examiners, showing a broad range of examiner interactions. Prosecution activity spans 7 distinct art units, reflecting the technical breadth of the company's biotechnology applications.
ANDERSON, REBECCA L is the busiest examiner, currently handling 2 busiest examiner pending office actions. With 9 pending office actions and 8 distinct examiners, the company's applications are being reviewed by a diverse group of USPTO personnel across 7 art units. The involvement of 7 distinct art units further underscores the breadth of the company's current examination landscape. ANDERSON, REBECCA L handles 2 busiest examiner pending office actions, which is the specific count for the busiest examiner in this portfolio.
Based on the USPTO statutory response window for each pending office action. 3 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 3 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 2 (20%) |
| §103 only | 3 (30%) |
| §112 only | 2 (20%) |
| Double-patenting + other | 2 (20%) |
| Multi-statute (no §101) | 1 (10%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| ANDERSON, REBECCA L | 3 | 73.3% | +23.7% |
| KIFLE, BRUCK | 1 | 79.3% | +15.8% |
| SKIBINSKY, ANNA | 1 | 39.1% | +29.3% |
| MCINTOSH III, TRAVISS C | 1 | 73.3% | +14.1% |
| ALBERTALLI, BRIAN LOUIS | 1 | 81.8% | +16.8% |
| WELLS, LAUREN QUINLAN | 1 | 49.4% | +59.7% |
| ABDALHAMEED, MANAHIL MIRGHANI ALI | 1 | 50.3% | +39.1% |
| NEWTON, CHAD A | 1 | 38.4% | +23.4% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17927234 | INTELLIGENT TRANSCRIPTION AND BIOMARKER ANALYSIS | ALBERTALLI, BRIAN LOUIS | 5d overdue |
| 17927462 | APPARATUSES, SYSTEMS, AND METHODS FOR BIOMARKER COLLECTION, BI-DIRECTIONAL PATIENT COMMUNICATION AND LONGITUDINAL PATIENT FOLLOW-UP | NEWTON, CHAD A | 29d |
| 18274066 | PSILOCYBIN THERAPY FOR TREATMENT RESISTANT DEPRESSION | SKIBINSKY, ANNA | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17927234 | INTELLIGENT TRANSCRIPTION AND BIOMARKER ANALYSIS | ALBERTALLI, BRIAN LOUIS | 5d overdue |
| 18032320 | USE OF BENZODIAZEPINES TO INCREASE SENSITIVITY TO PSILOCYBIN FOLLOWING A CHRONIC SSRI REGIMEN | WELLS, LAUREN QUINLAN | 2d overdue |
| 17927462 | APPARATUSES, SYSTEMS, AND METHODS FOR BIOMARKER COLLECTION, BI-DIRECTIONAL PATIENT COMMUNICATION AND LONGITUDINAL PATIENT FOLLOW-UP | NEWTON, CHAD A | 29d |
| 19661115 | PREPARATION OF PSILOCYBIN, DIFFERENT POLYMORPHIC FORMS, INTERMEDIATES, FORMULATIONS AND THEIR USE | ANDERSON, REBECCA L | — |
| 19629952 | PREPARATION OF PSILOCYBIN, DIFFERENT POLYMORPHIC FORMS, INTERMEDIATES, FORMULATIONS AND THEIR USE | ANDERSON, REBECCA L | — |
| 19296560 | PREPARATION OF PSILOCYBIN, DIFFERENT POLYMORPHIC FORMS, INTERMEDIATES, FORMULATIONS AND THEIR USE | ANDERSON, REBECCA L | — |
| 18703950 | TREATMENT OF TREATMENT RESISTANT DEPRESSION WITH PSILOCYBIN | KIFLE, BRUCK | — |
| 18274066 | PSILOCYBIN THERAPY FOR TREATMENT RESISTANT DEPRESSION | SKIBINSKY, ANNA | — |
| Art Unit | Apps |
|---|---|
| 1626 | 3 |
| 1622 | 2 |
| 1624 | 1 |
| 1635 | 1 |
| 1693 | 1 |
| 2656 | 1 |
| 3681 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19661115 | PREPARATION OF PSILOCYBIN, DIFFERENT POLYMORPHIC FORMS, INTERMEDIATES, FORMULATIONS AND THEIR USE | ANDERSON, REBECCA L | 1626 | §103Other | Non-Final OA | — | Pending | Apr 28, 2026 |
| 19629952 | PREPARATION OF PSILOCYBIN, DIFFERENT POLYMORPHIC FORMS, INTERMEDIATES, FORMULATIONS AND THEIR USE | ANDERSON, REBECCA L | 1626 | §112Other | Final Rejection | — | Pending | Mar 26, 2026 |
| 19296560 | PREPARATION OF PSILOCYBIN, DIFFERENT POLYMORPHIC FORMS, INTERMEDIATES, FORMULATIONS AND THEIR USE | ANDERSON, REBECCA L | 1626 | §112DP | Final Rejection | — | Pending | Aug 11, 2025 |
| 18703950 | TREATMENT OF TREATMENT RESISTANT DEPRESSION WITH PSILOCYBIN | KIFLE, BRUCK | 1624 | §103 | Non-Final OA | — | Pending | Apr 23, 2024 |
| 18274066 | PSILOCYBIN THERAPY FOR TREATMENT RESISTANT DEPRESSION | SKIBINSKY, ANNA | 1635 | §101§103 | Non-Final OA | — | Pending | Jul 25, 2023 |
| 18267827 | MODIFIED INDOLE ALKALOIDS FOR THERAPEUTIC USES | MCINTOSH III, TRAVISS C | 1693 | §112 | Non-Final OA | — | Pending | Jun 16, 2023 |
| 17927234 | INTELLIGENT TRANSCRIPTION AND BIOMARKER ANALYSIS | ALBERTALLI, BRIAN LOUIS | 2656 | §102§103 | Non-Final OA | 5d overdue | Pending | Jun 01, 2023 |
| 18032320 | USE OF BENZODIAZEPINES TO INCREASE SENSITIVITY TO PSILOCYBIN FOLLOWING A CHRONIC SSRI REGIMEN | WELLS, LAUREN QUINLAN | 1622 | §103 | Final Rejection | 2d overdue | Pending | Apr 17, 2023 |
| 18021243 | NOVEL PSILOCIN DERIVATIVES HAVING PRODRUG PROPERTIES | ABDALHAMEED, MANAHIL MIRGHANI ALI | 1622 | §102§103DP | Non-Final OA | — | Pending | Feb 14, 2023 |
| 17927462 | APPARATUSES, SYSTEMS, AND METHODS FOR BIOMARKER COLLECTION, BI-DIRECTIONAL PATIENT COMMUNICATION AND LONGITUDINAL PATIENT FOLLOW-UP | NEWTON, CHAD A | 3681 | §101§103 | Non-Final OA | 29d | Pending | Nov 23, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialCompass Pathfinder Limited has 10 pending office actions as of October 2026, spread across 7 art units and 8 examiners.
Rebecca L Anderson has the most, with 3 of Compass Pathfinder Limited's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.